Decreased expression of sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: A correlation with BDNF expression

PLoS ONE

Volumn 3, Issue 3, 2008, Pages

  Pillai, Anilkumar ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT; OLANZAPINE; SPROUTY PROTEIN; SPROUTY2 PROTEIN; PRIMER DNA; SIGNAL PEPTIDE; SPRY2 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EXPOSURE; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREFRONTAL CORTEX; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; ANIMAL; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

RATTUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASE SEQUENCE; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DNA PRIMERS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PREFRONTAL CORTEX; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 46349086695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001784     Document Type: Article

References (66)

1. Ben-Shachar D, Laifenfeld D (2004) Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol 59: 273-296.
2. Eastwood SL (2004) The synaptic pathology of schizophrenia: is aberrant neurodevelopment and plasticity to blame? Int Rev Neurobiol 59: 47-72.
3. Arnold SE, Talbot K, Hahn CG (2005) Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Prog Brain Res 147: 319-345.
4. Rylett RJ, Williams LR (1994) Role of neurotrophins in cholinergic-neuron function in the adult and aged CNS. Trends Neurosci 17: 486-490.
5. Cellerino A, Carroll P, Thoenen H, Barde YA (1997) Reduced size of retinal ganglion cell axons and hypomyclination in mice lacking brain-derived neurotrophic factor. Mol Cell Neurosci 9: 397-408.
6. Pizzorusso T, Maffei L (1996) Plasticity in the developing visual system. Curr Opin Neurol 9: 122-125.
7. Bramham CR, Messaoudi E (2005) BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 76: 99-125.
8. Shoval G, Weizman A (2005) The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 15: 319-329.
9. Buckley PF, Mahadik S, Pillai A, Terry A Jr (2007) Neurotrophins and schizophrenia. Schizophr Res 94: 1-11.
10. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, et al. (2003) Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8: 592-610.
11. Weickert CS, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, et al. (2005) Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 10: 637-650.
12. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, et al. (2005) Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25: 372-383.
13. Durany T, Michel R, Zochling KW, Boissl FF, Cruz-Sanchez F, et al. (2001) Brain derived neurotrophic factor and neurotrophin-3 in schizophrenic psychoses. Schizophrenia Res 52: 79-86.
14. Iritani S, Niizato K, Hawa H, et al. (2003) Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27: 801-807.
15. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, et al. (2000) Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry 5: 293-300.
16. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, et al. (2002) Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res 110: 249-257.
17. Tan YL, Zhou DF, Zhang XY (2005) Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 74: 263-270.
18. Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, et al. (2007) Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res 4: 31-35.
19. Shimizu E, Hashimoto K, Watanabe H, Komatsu N, Okamura N, et al. (2003) Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenia are indistinguishable from controls. Neurosci Lett 351: 111-114.
20. Jockers-Scherübl MC, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, et al. (2004) Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 371: 79-83.
21. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S (2007) Brain derived neurotrophic factor in first-episode psychosis. Schizophr Res 91: 1-5.
22. Angelucci F, Aloe L, Gruber SH, Fiore M, Mathe AA (2000) Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions. Int J Neuropsychopharmacol 3: 13-25.
23. Pillai A, Terry AV Jr, Mahadik SP (2006) Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 82: 95-106.
24. Mason JM, Morrison DJ, Basson MA, Licht JD (2006) Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell Biol 16: 45-54.
25. Kim HJ, Bar-Sagi D (2004) Modulation of signalling by Sprouty: a developing story. Nat Rev Mol Cell Biol 5: 441-450.
26. Gross I, Armant O, Benosman S, de Aguilar JL, Freund JN, et al. (2007) Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death Differ 14: 1802-1812.
27. Bunney WE, Bunney BG (2000) Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia. Brain Res Brain Res Rev 31: 138-146.
28. Xu B, Wratten N, Charych EI, Buyske S, Firestein BL, et al. (2005) Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Med 2: c263.
29. De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH (2005) Tryptophan hydroxylase 2 gene expression and promoter polymorphisms in bipolar disorder and schizophrenia. Psychopharmacology (Berl) 183: 378-382.
30. Mueller HT, Meador-WoodrufF JH (2004) NR3A NMDA receptor subunit mRNA expression in schizophrenia, depression and bipolar disorder. Schizophr Res 71: 361-370.
31. Gross I, Bassit B, Benezra M, Licht JD (2001) Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem 276: 46460-46468.
32. Impagnatiello MA, Weitzer S, Gannon G, Compagni A, Cotten M, et al. (2001) Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol 152: 1087-1098.
33. Sasaki A, Taketomi T, Wakioka T, Kato R, Yoshimura A (2001) Identification of a dominant negative mutant of Sprouty that potentiates fibroblast growth factor- but not epidermal growth factor-induced ERK activation. J Biol Chem 276: 36804-36808.
34. Xing J, Kornhauser JM, Xia Z, Thiele EA, Greenberg ME (1998) Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. Mol Cell Biol 18: 1946-1955.
35. Merchant JL, Du M, Todisco A (1999) Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem Biophys Res Commun 254: 454-461.
36. Jarskog LF, Gilmore JH, Glantz LA, Gable KL, German TT, et al. (2007) Caspase-3 activation in rat frontal cortex following treatment with typical and atypical antipsychotics. Neuropsychopharmacology 32: 95-102.
37. Pillai A, Dhandapani KM, Pillai BA, Terry AV Jr, Mahadik SP (2007) Erythropoietin Prevents Haloperidol Treatment-Induced Neuronal Apoptosis through Regulation of BDNF. Neuropsychopharmacology Sep 5.
38. Green W, Patil P, Marsden CA, Bennett GW, Wigmore PM (2006) Treatment with olanzapine increases cell proliferation in the subventricular zone and prefrontal cortex. Brain Res 1070: 242-245.
39. Kodama M, Fujioka T, Duman RS (2004) Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 56: 570-580.
40. Ding W, Shi W, Bellusci S, Groffen J, Heisterkamp N, et al. (2007) Sprouty2 downregulation plays a pivotal role in mediating crosstalk between TGF-beta 1 signaling and EGF as well as FGF receptor tyrosine kinase-ERK pathways in mesenchymal cells. J Cell Physiol 212: 796-806.
41. Manji HK, Gottesman II, Gould TD (2003) Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci STKE 2003: pe49.
42. Winder DG, Sweatt JD (2001) Roles of serine/threonine phosphatases in hippocampal synaptic plasticity. Nat Rev Neurosci 2: 461-474.
43. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, et al. (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 71: 877-892.
44. Corfas G, Roy K, Buxbaum JD (2004) Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 7: 575-580.
45. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, et al. (2001) Genome-wide expression analysis reveals dysregulation of myelination-relatedgenes in chronic schizophrenia. Proc Natl Acad Sci U S A 98: 4746-4751.
46. Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, et al. (2004) Axonal neuregulin-I regulates myelin sheath thickness. Science 304: 700-703.
47. Davis KL, Stewart DG, Friedma JI, Buchsbaum M, Harvey PD, et al. (2003) White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 60: 443-456.
48. Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, et al. (2002) Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry 7: 673-682.
49. Hashimoto K, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. (2005) No changes in serum epidermal growth factor levels in patients with schizophrenia. Psychiatry Res 135: 257-260.
50. Hashimoto R, Numakawa T, Ohnishi T, Kumamaru E, Yagasaki Y, et al. (2006) Impact of the DISCI Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum Mol Genet 15: 3024-3033.
51. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103: 211-225.
52. Sweatt JD (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14: 311-317.
53. Yusoff P, Lao DH, Ong SH, Wong ES, Lim J, et al. (2002) Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf J Biol Chem 277: 3195-3201.
54. Tefft D, Lee M, Smith S, Crowe DL, Bellusci 5, et al. (2002) mSprouty2 inhibits FGF1O-activated MAP kinase by differentially binding to upstream target proteins. Am J Physiol Lung Cell Mol Physiol. 283: L700-706.
55. Wong ES, Fong CW, Lim J, Yusoff P, Low BC, et al. (2002) Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J 21: 4796-4808.
56. Kyosseva SV (2004) The role of the extracellular signal-regulated kinase pathway in cerebellar abnormalities in schizophrenia. Cerebellum 3: 94-99.
57. Browning JL, Patel T, Brandt PC, Young KA, Holcomb LA, et al. (2005) Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic, actions. Biol Psychiatry 57: 617-623.
58. Yang BH, Son H, Kim SH, Nam JH, Choi JH, et al. (2004) Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration. Psychiatry Clin Neurosci 58: 262-267.
59. Pozzi L, Håkansson K, Usiello A, Borgkvist A, Lindskog M, et al. (2003) Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum, J Neurochem 86: 451-459.
60. Torrey EF, Mortensen PB, Pedersen CB, Wohlfahrt J, Melbye M (2001) Risk factors and confounders in the geographical clustering of schizophrenia. Schizophr Res 49: 295-299.
61. Didriksen M (1995) Effects of antipsychotics on cognitive behavior in rats using the delayed non-match to position paradigm. Eur J Pharmacol 28: 241-250.
62. Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW (1996) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, aladrenergic and muscarinic receptors in vivo in rats. Psychopharmacology (Berl.) 124: 87-94.
63. Skarsfeldt T (1996) Differential effect of antipsychotics on place navigation of rats in Morris water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology (Berl.) 124: 126-133.
64. Kinon BJ, Lieberman JA (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 124: 2-34.
65. Terry AV Jr, Hill WD, Parikh V, Waller JL, Evans DR, et al. (2003) Differential effects of haloperidol, risperidone, and clozapine exposure on cholinergic markets and spatial learning performance in rats. Neuropsychopharmacology 28: 300-309.
66. Terry AV Jr, Hill WD, Parish V, Evans DR, Waller JL, et al. (2002) Differential effects of chronic haloperidol and olanzapine exposure on brain cholinergic markers and spatial learning in rats. Psychopharmacology (Berl) 164: 360-368.